Avid Bioservices Inc (CDMO)

[cjgaddy]

KOL Dr. John Nemunaitis: in the 9-10-12 Financials & Developments PR ( http://tinyurl.com/8nkwrml ), there was this quote by Dr. John Nemunaitis about the Bavi 2nd-Line NSCLC data presented by Dr. David Gerber in his late-breaker plenary talk the ASTRO/Thoracic Symposium in Chicago on Sept7:

"The unique immune directed attack of bavituximab and preliminary survival advantage of far greater magnitude than what has been observed historically with anti-angiogenesis agents provide potentially yet another example of clinically relevant immune directed therapy moving forward," said John Nemunaitis, M.D., executive director of the Mary Crowley Cancer Research Centers and an investigator in Peregrine's Phase II bavituximab 2nd-Line NSCLC clinical trial [ http://clinicaltrials.gov/ct2/show/NCT01138163 ].

= = = = = = = = = = = = =
A bit of Googling and it’s obvious he is quite the oncology heavyweight & KOL...

Mary Crowley Cancer Research Centers (Dallas TX)
http://www.marycrowley.org
Pioneering. Personalized. Targeted.
Mary Crowley Cancer Research Centers offers patients access to personalized, innovative clinical trials under the oversight of the U.S. FDA, using the newest therapies that target the molecular pathways which impact cancer growth. The patients provide the inspiration for our pursuit of a cure. Science is the premise. Therapies provide the path. Hope for a better future is the journey shared with each patient. We encourage you to learn about who we are, what we do and what is needed in the fight against cancer.
- - - - - - - -
JOHN NEMUNAITIS, M.D.
Oncologist & Executive Medical Director
Dr. Nemunaitis has been exploring novel targeted therapies for treating cancer patients for more than 20 years. In 1993, he came to Dallas to establish the clinical research program for Texas Oncology Physicians Association (TOPA). He later established a not-for-profit translational research program, which later became Mary Crowley Cancer Research Centers.

In 2005, Dr. Nemunaitis co-founded a molecular therapeutic & vaccine biotechnology company with GMP manufacturing capacity called Gradalis, Inc. [ http://www.gradalisinc.com ] To date, Dr. Nemunaitis has authored more than 282 peer-reviewed publications and 39 book chapters. He has conducted 350 FDA-regulated trials including investigator-initiated IND trials, overseen FDA-sponsored experimental treatment of more than 4,100 cancer patients at Mary Crowley, has carried out 20 government regulatory presentations (i.e., FDA, RAC) for biotechnology product development, and is the inventor or co-inventor of seven new patents involving novel molecular therapies.

His research focus is clinical in orientation and involves determination of molecular signals in order to optimize targeted therapy, development of RNAi based therapeutics, and cancer vaccine approaches. He was also elected as a member of the Board of Directors of the American Society of Gene and Cell Therapy ASGCT, as well as a committee member of the Western Institutional Review Board (WIRB).

Dr. Nemunaitis received his B.A. and M.D. degrees from Case Western Reserve University in Cleveland, Ohio. He completed his residency at Boston City Hospital and then performed his Hematology and Oncology fellowship at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle from 1988 to 1993.
http://www.marycrowley.org/en/About%20Us/Our%20Team/Executive%20Team/John%20Nemunaitis.aspx